• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Sanofi - American Depositary Shares (NQ: SNY )

    47.71 +0.21 (+0.44%)
    Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 2,486,786
    Open 46.92
    Bid (Size) 47.72 (6)
    Ask (Size) 47.74 (62)
    Prev. Close 47.50
    Today's Range 46.89 - 47.90
    52wk Range 45.22 - 58.97
    Shares Outstanding 1,250,690,553
    Dividend Yield 4.27%
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio?
    The top-performing stocks last week were TEVA, KVYO, DRI, DOCS, BIRK, JBL, NBIX, GME, RDY, and LI. Did you have any of them in your portfolio? 
    Via Benzinga
    Why Cytokinetics Stock Was a Nearly 5% Winner Today
    Via The Motley Fool

    Performance

    YTD
    -4.58%
    -4.58%
    1 Month
    -0.56%
    -0.56%
    3 Month
    -16.92%
    -16.92%
    6 Month
    -2.57%
    -2.57%
    1 Year
    -2.11%
    -2.11%

    More News

    Read More
    In a market where value is scarce, NASDAQ:SNY offers a refreshing opportunity with its solid fundamentals.
    Via Chartmill
    Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases
    Via Benzinga
    RCI Hospitality, Quantum Computing, Teva Pharmaceutical, Tesla And Other Big Stocks Moving Higher On Monday
    Via Benzinga
    Why NASDAQ:SNY qualifies as a good dividend investing stock.
    Via Chartmill
    Balancing Dividends and Fundamentals: The Case of NASDAQ:SNY.
    Via Chartmill
    Teva Catapults 20%, Nearing A Five-Year High, After Scoring A Win With Sanofi-Tied Drug
    Via Investor's Business Daily
    Why Are Teva And Sanofi Stocks Trading Higher On Tuesday?
    Via Benzinga
    Sanofi's 340B Credit Proposal Draws Federal Warning For Statutory Violation
    Via Benzinga
    Kennedy's Lawyer Urges FDA To Revoke Polio Vaccine Approval, Endangering Millions Of Children
    Via Benzinga
    Topics Government
    Exposures Political Product Safety
    2 Beaten-Down "Pandemic Stocks" to Consider for Contrarian Investors
    Via The Motley Fool
    Jim Cramer: This Energy Stock Is A 'Winner,' But Navitas Semiconductor Is 'Losing A Lot Of Money'
    Via Benzinga
    NVIDIA Invested in These 2 AI Stocks, Should You?
    Via MarketBeat
    Topics Artificial Intelligence
    Exposures Artificial Intelligence Product Safety
    NASDAQ:SNY is probably undervalued for the fundamentals it is displaying.
    Via Chartmill
    Bird Flu Found In Raw Milk Leads To Recall In California
    Via Benzinga
    Topics Product Recall
    Exposures Legal Product Safety
    Big Pharma's Pharmacy-Benefit Managers Accuse FTC of Overreach In Effort to Reshape Drug Rebate System
    Via Benzinga
    Mutated Bird Flu Case In California Puts Humans At Increased Risk, So Which Companies Are Developing Vaccines?
    Via Benzinga
    European And US Vaccine Stocks Are Under Pressure - Here's WHy
    Via Benzinga
    Exposures Product Safety
    FDA To Revisit Regeneron/Sanofi's Dupixent For Rare Skin Disease
    Via Benzinga
    Exposures Product Safety
    Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
    From Regeneron Pharmaceuticals, Inc.
    Via GlobeNewswire
    Viking Fund Management Sells Big Oil Stocks In Q3, Cuts Tesla Position In Half, Adds To Largest Position Broadcom
    Via Benzinga
    Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease
    Via Benzinga
    Humanitarian Organization Criticizes Eli Lilly, Novo Nordisk And Sanofi Of Having 'Double Standards' For High Insulin Price
    Via Benzinga
    Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
    Via Benzinga
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.